{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:22:16Z","timestamp":1793146936065,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1245\/s10434-026-20021-8","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:44:38Z","timestamp":1782513878000},"page":"9386-9395","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cyclin E1 Expression Predicts Poorer Outcome in HER2-positive Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy"],"prefix":"10.1245","volume":"33","author":[{"given":"Yuko","family":"Ueki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8935-0768","authenticated-orcid":false,"given":"Yoshiya","family":"Horimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Men","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Ushiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Ishizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Onagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8544-9370","authenticated-orcid":false,"given":"Takuo","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Kawate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9226-895X","authenticated-orcid":false,"given":"Junichiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goro","family":"Kutomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"issue":"11","key":"20021_CR1","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1093\/annonc\/mdq096","volume":"21","author":"RB Costa","year":"2010","unstructured":"Costa RB, Kurra G, Greenberg L, Geyer CE. Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Ann Oncol. 2010;21(11):2153\u201360.","journal-title":"Ann Oncol."},{"key":"20021_CR2","doi-asserted-by":"crossref","unstructured":"Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012;2012(4):Cd006243.","DOI":"10.1002\/14651858.CD006243.pub2"},{"key":"20021_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2025.104507","volume":"82","author":"S Palmi","year":"2025","unstructured":"Palmi S, Murtola TJ, Murto M, Huhtala H, Arponen O, Jukkola A. The association between intrinsic breast cancer subtypes, mammography screening and prognosis: a large population-based real world cohort study. Breast. 2025;82:104507.","journal-title":"Breast."},{"issue":"1","key":"20021_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25\u201332.","journal-title":"Lancet Oncol."},{"issue":"6","key":"20021_CR5","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","volume":"17","author":"L Gianni","year":"2016","unstructured":"Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17(6):791\u2013800.","journal-title":"Lancet Oncol."},{"issue":"1","key":"20021_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12885-024-11851-4","volume":"24","author":"GP Dowling","year":"2024","unstructured":"Dowling GP, Toomey S, Bredin P, Parker I, Mulroe E, Marron J, et al. Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study). BMC Cancer. 2024;24(1):91.","journal-title":"BMC Cancer."},{"key":"20021_CR7","doi-asserted-by":"crossref","unstructured":"Harbeck N, Modi S, Pusztai L, Ohno S, Wu J, Kim SB, et al. Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial. Ann Oncol. 2025.","DOI":"10.1016\/j.annonc.2025.08.720"},{"key":"20021_CR8","doi-asserted-by":"crossref","unstructured":"Swain SM, Macharia H, Cortes J, Dang C, Gianni L, Hurvitz SA, et al. Event-free survival in patients with early her2-positive breast cancer with a pathological complete response after HER2-targeted therapy: a pooled analysis. Cancers (Basel). 2022;14(20).","DOI":"10.3390\/cancers14205051"},{"issue":"3","key":"20021_CR9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1056\/NEJMoa2406070","volume":"392","author":"CE Geyer Jr","year":"2025","unstructured":"Geyer CE Jr, Untch M, Huang CS, Mano MS, Mamounas EP, Wolmark N, et al. Survival with trastuzumab emtansine in residual HER2-positive breast cancer. N Engl J Med. 2025;392(3):249\u201357.","journal-title":"N Engl J Med."},{"issue":"1","key":"20021_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10549-014-2907-9","volume":"145","author":"M Takada","year":"2014","unstructured":"Takada M, Ishiguro H, Nagai S, Ohtani S, Kawabata H, Yanagita Y, et al. Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study). Breast Cancer Res Treat. 2014;145(1):143\u201353.","journal-title":"Breast Cancer Res Treat."},{"issue":"1","key":"20021_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41523-023-00525-2","volume":"9","author":"J Huober","year":"2023","unstructured":"Huober J, van Mackelenbergh M, Schneeweiss A, Seither F, Blohmer JU, Denkert C, et al. Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy. NPJ Breast Cancer. 2023;9(1):23.","journal-title":"NPJ Breast Cancer."},{"issue":"4","key":"20021_CR12","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3892\/ol.2023.14021","volume":"26","author":"EN H\u00e4nnik\u00e4inen","year":"2023","unstructured":"H\u00e4nnik\u00e4inen EN, Mattson J, Karihtala P. Predictors of successful neoadjuvant treatment in HER2-positive breast cancer. Oncol Lett. 2023;26(4):434.","journal-title":"Oncol Lett."},{"issue":"28","key":"20021_CR13","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","volume":"25","author":"WF Symmans","year":"2007","unstructured":"Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25(28):4414\u201322.","journal-title":"J Clin Oncol."},{"issue":"5","key":"20021_CR14","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0960-9776(03)00106-1","volume":"12","author":"KN Ogston","year":"2003","unstructured":"Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003;12(5):320\u20137.","journal-title":"Breast."},{"issue":"4","key":"20021_CR15","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1007\/s12282-025-01694-7","volume":"32","author":"M Uematsu","year":"2025","unstructured":"Uematsu M, Nakajima H, Miyake H, Wakabayashi M, Funasaka C, Kondoh C, et al. Digitally quantified area of residual tumor after neoadjuvant chemotherapy in HER2-positive breast cancer. Breast Cancer. 2025;32(4):716\u201327.","journal-title":"Breast Cancer."},{"key":"20021_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.humpath.2017.02.005","volume":"63","author":"E Tokuda","year":"2017","unstructured":"Tokuda E, Horimoto Y, Arakawa A, Himuro T, Senuma K, Nakai K, et al. Differences in Ki67 expressions between pre- and post-neoadjuvant chemotherapy specimens might predict early recurrence of breast cancer. Hum Pathol. 2017;63:40\u20135.","journal-title":"Hum Pathol."},{"issue":"7","key":"20021_CR17","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1245\/s10434-016-5164-9","volume":"23","author":"T Himuro","year":"2016","unstructured":"Himuro T, Horimoto Y, Arakawa A, Matsuoka J, Tokuda E, Tanabe M, et al. Activated caspase 3 expression in remnant disease after neoadjuvant chemotherapy may predict outcomes of breast cancer patients. Ann Surg Oncol. 2016;23(7):2235\u201341.","journal-title":"Ann Surg Oncol."},{"issue":"17","key":"20021_CR18","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.1158\/1078-0432.CCR-23-0480","volume":"29","author":"F Miglietta","year":"2023","unstructured":"Miglietta F, Ragazzi M, Fernandes B, Griguolo G, Massa D, Girardi F, et al. A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ Breast Cancer. Clin Cancer Res. 2023;29(17):3429\u201337.","journal-title":"Clin Cancer Res."},{"key":"20021_CR19","doi-asserted-by":"crossref","unstructured":"Honma N, Yoshida M, Kinowaki K, Horii R, Katsurada Y, Murata Y, et al. The Japanese breast cancer society clinical practice guidelines for pathological diagnosis of breast cancer, 2022 edition. Breast Cancer. 2024;31(1):8\u201315.","DOI":"10.1007\/s12282-023-01518-6"},{"issue":"22","key":"20021_CR20","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.22.02864","volume":"41","author":"AC Wolff","year":"2023","unstructured":"Wolff AC, Somerfield MR, Dowsett M, Hammond MEH, Hayes DF, McShane LM, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists Guideline Update. J Clin Oncol. 2023;41(22):3867\u201372.","journal-title":"J Clin Oncol."},{"issue":"3","key":"20021_CR21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S1658-3876(10)50020-7","volume":"3","author":"HL G\u00f3mez","year":"2010","unstructured":"G\u00f3mez HL, Casta\u00f1eda CA, Vigil CE, Vidaurre T, Velarde RG, Cruz WR, et al. Prognostic effect of hormone receptor status in early HER2 positive breast cancer patients. Hematol Oncol Stem Cell Ther. 2010;3(3):109\u201315.","journal-title":"Hematol Oncol Stem Cell Ther."},{"issue":"4","key":"20021_CR22","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.breast.2014.03.008","volume":"23","author":"M Tanioka","year":"2014","unstructured":"Tanioka M, Sasaki M, Shimomura A, Fujishima M, Doi M, Matsuura K, et al. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status. Breast. 2014;23(4):466\u201372.","journal-title":"Breast."},{"issue":"7","key":"20021_CR23","doi-asserted-by":"publisher","first-page":"9813","DOI":"10.1007\/s13277-016-4870-z","volume":"37","author":"S Luhtala","year":"2016","unstructured":"Luhtala S, Staff S, Tanner M, Isola J. Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer. Tumour Biol. 2016;37(7):9813\u201323.","journal-title":"Tumour Biol."},{"issue":"20","key":"20021_CR24","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1056\/NEJMoa021153","volume":"347","author":"K Keyomarsi","year":"2002","unstructured":"Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med. 2002;347(20):1566\u201375.","journal-title":"N Engl J Med."},{"issue":"8","key":"20021_CR25","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.3390\/cancers12082268","volume":"12","author":"C Lee","year":"2020","unstructured":"Lee C, Fernandez KJ, Alexandrou S, Sergio CM, Deng N, Rogers S, et al. Cyclin E2 promotes whole genome doubling in breast cancer. Cancers (Basel). 2020;12(8):2268.","journal-title":"Cancers (Basel)."},{"issue":"7","key":"20021_CR26","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1002\/jcb.25462","volume":"117","author":"GW Peek","year":"2016","unstructured":"Peek GW, Tollefsbol TO. Combinatorial PX-866 and raloxifene decrease Rb phosphorylation, cyclin E2 transcription, and proliferation of MCF-7 breast cancer cells. J Cell Biochem. 2016;117(7):1688\u201396.","journal-title":"J Cell Biochem."},{"issue":"14","key":"20021_CR27","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1200\/JCO.18.00925","volume":"37","author":"NC Turner","year":"2019","unstructured":"Turner NC, Liu Y, Zhu Z, Loi S, Colleoni M, Loibl S, et al. Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2019;37(14):1169\u201378.","journal-title":"J Clin Oncol."},{"issue":"11","key":"20021_CR28","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.ccell.2024.09.009","volume":"42","author":"R Kudo","year":"2024","unstructured":"Kudo R, Safonov A, Jones C, Moiso E, Dry JR, Shao H, et al. Long-term breast cancer response to CDK4\/6 inhibition defined by TP53-mediated geroconversion. Cancer Cell. 2024;42(11):1919-35.e9.","journal-title":"Cancer Cell."},{"issue":"6","key":"20021_CR29","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1080\/07357900600894799","volume":"24","author":"L Wang","year":"2006","unstructured":"Wang L, Shao ZM. Cyclin e expression and prognosis in breast cancer patients: a meta-analysis of published studies. Cancer Invest. 2006;24(6):581\u20137.","journal-title":"Cancer Invest."},{"issue":"6","key":"20021_CR30","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1007\/s13277-013-0915-8","volume":"34","author":"S Gao","year":"2013","unstructured":"Gao S, Ma JJ, Lu C. Prognostic value of cyclin E expression in breast cancer: a meta-analysis. Tumour Biol. 2013;34(6):3423\u201330.","journal-title":"Tumour Biol."},{"issue":"27","key":"20021_CR31","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1038\/onc.2010.151","volume":"29","author":"EA Mittendorf","year":"2010","unstructured":"Mittendorf EA, Liu Y, Tucker SL, McKenzie T, Qiao N, Akli S, et al. A novel interaction between HER2\/neu and cyclin E in breast cancer. Oncogene. 2010;29(27):3896\u2013907.","journal-title":"Oncogene."},{"issue":"43","key":"20021_CR32","doi-asserted-by":"publisher","first-page":"6573","DOI":"10.1038\/sj.onc.1205847","volume":"21","author":"JF Timms","year":"2002","unstructured":"Timms JF, White SL, O\u2019Hare MJ, Waterfield MD. Effects of ErbB-2 overexpression on mitogenic signalling and cell cycle progression in human breast luminal epithelial cells. Oncogene. 2002;21(43):6573\u201386.","journal-title":"Oncogene."},{"issue":"9","key":"20021_CR33","doi-asserted-by":"publisher","first-page":"3761","DOI":"10.1073\/pnas.1014835108","volume":"108","author":"M Scaltriti","year":"2011","unstructured":"Scaltriti M, Eichhorn PJ, Cort\u00e9s J, Prudkin L, Aura C, Jim\u00e9nez J, et al. Cyclin E amplification\/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci U S A. 2011;108(9):3761\u20136.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"5","key":"20021_CR34","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.immuni.2016.10.032","volume":"45","author":"G Plitas","year":"2016","unstructured":"Plitas G, Konopacki C, Wu K, Bos PD, Morrow M, Putintseva EV, et al. Regulatory T cells exhibit distinct features in human breast cancer. Immunity. 2016;45(5):1122\u201334.","journal-title":"Immunity."},{"key":"20021_CR35","doi-asserted-by":"publisher","first-page":"1263537","DOI":"10.3389\/fimmu.2023.1263537","volume":"14","author":"P Huang","year":"2023","unstructured":"Huang P, Zhou X, Zheng M, Yu Y, Jin G, Zhang S. Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer. Front Immunol. 2023;14:1263537.","journal-title":"Front Immunol."},{"issue":"1","key":"20021_CR36","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13058-022-01563-7","volume":"24","author":"H Onagi","year":"2022","unstructured":"Onagi H, Horimoto Y, Sakaguchi A, Ikarashi D, Yanagisawa N, Nakayama T, et al. High platelet-to-lymphocyte ratios in triple-negative breast cancer associates with immunosuppressive status of TILs. Breast Cancer Res. 2022;24(1):67.","journal-title":"Breast Cancer Res."},{"issue":"9","key":"20021_CR37","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/s41423-023-01036-7","volume":"20","author":"J Wang","year":"2023","unstructured":"Wang J, Zhao X, Wan YY. Intricacies of TGF-\u03b2 signaling in Treg and Th17 cell biology. Cell Mol Immunol. 2023;20(9):1002\u201322.","journal-title":"Cell Mol Immunol."},{"key":"20021_CR38","doi-asserted-by":"publisher","first-page":"1457189","DOI":"10.3389\/fimmu.2024.1457189","volume":"15","author":"J Ge","year":"2024","unstructured":"Ge J, Yin X, Chen L. Regulatory T cells: masterminds of immune equilibrium and future therapeutic innovations. Front Immunol. 2024;15:1457189.","journal-title":"Front Immunol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20021-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20021-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20021-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:52:19Z","timestamp":1789667539000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20021-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["20021"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20021-8","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study was approved by the Institutional Review Board of our hospital (Approval No.: H19-0289).","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}